Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | DUT | P33316 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | DNMT1 | P26358 | 3/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15320020 | 1.00 | ALDH1A1 (0.36) | ALDH1A1CASP3TDP1LMNAUSP2 | |
| SCHEMBL2507608 | 1.00 | ALDH1A1 (0.36) | ALDH1A1CASP3TDP1LMNAUSP2 | |
| SCHEMBL20040523 | 0.86 | TDP1 (0.35) | ALDH1A1TDP1LMNAUSP2DUT | |
| SCHEMBL17591381 | 0.79 | ALDH1A1 (0.42) | ALDH1A1CASP3TDP1LMNANPSR1 | |
| SCHEMBL2321878 | 0.78 | ALDH1A1 (0.34) | ALDH1A1MAPT | |
| SCHEMBL2511661 | 0.78 | CDC25A (0.34) | ALDH1A1 | |
| SCHEMBL2511664 | 0.78 | CDC25A (0.34) | ALDH1A1 | |
| SCHEMBL2321882 | 0.78 | ALDH1A1 (0.34) | ALDH1A1MAPT | |
| SCHEMBL2511659 | 0.78 | CDC25A (0.34) | ALDH1A1 | |
| SCHEMBL2510637 | 0.78 | ALDH1A1 (0.34) | ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111196808-B | Diazabicyclo compounds and their use | 南京圣和药业股份有限公司 | 2022-10-18 | — | — | CN | disclosed |
| EP-3512851-B1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | ENTASIS THERAPEUTICS LTD (GB) | 2022-07-06 | — | — | EP | disclosed |
| CN-114591223-A | Beta-lactamase inhibitor compounds | 恩塔西斯治疗有限公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-109715630-B | Beta-lactamase inhibitor compounds | 恩塔西斯治疗有限公司 | 2022-02-22 | — | — | CN | disclosed |
| US-10800778-B2 | Beta-lactamase inhibitor compounds | ENTASIS THERAPEUTICS LIMITED (GB) | 2020-10-13 | — | — | US | disclosed |
| CN-111196808-A | Diazabicyclo compounds and their use | 南京圣和药业股份有限公司 | 2020-05-26 | — | — | CN | disclosed |
| EP-3512851-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | Entasis Therapeutics Limited (GB) | 2019-07-24 | — | — | EP | disclosed |
| US-20190202832-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | ENTASIS THERAPEUTICS LIMITED (GB) | 2019-07-04 | — | — | US | disclosed |
| EP-2534140-B1 | EFFICIENT METHODS FOR Z- OR CIS-SELECTIVE CROSS-METATHESIS | TRUSTEES BOSTON COLLEGE (US) | 2018-04-11 | — | — | EP | disclosed |
| WO-2018053215-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | ENTASIS THERAPEUTICS LIMITED (GB) | 2018-03-22 | — | — | WO | disclosed |
| EP-2834239-B1 | HETEROBICYCLIC COMPOUNDS AS BETA-LACTAMASE INHIBITORS | ENTASIS THERAPEUTICS LTD (GB) | 2017-12-27 | — | — | EP | disclosed |
| US-9623014-B2 | β-lactamase inhibitor compounds | ENTASIS THERAPEUTICS LIMITED (GB) | 2017-04-18 | — | — | US | disclosed |
| US-20160175290-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | ASTRAZENECA PHARMACEUTICALS LP | 2016-06-23 | — | — | US | disclosed |
| US-9309245-B2 | Beta-lactamase inhibitor compounds | ENTASIS THERAPEUTICS LIMITED (GB) | 2016-04-12 | — | — | US | disclosed |
| US-20150073011-A1 | Beta-Lactamase Inhibitor Compounds | ASTRAZENECA AB (SE) | 2015-03-12 | — | — | US | disclosed |
| EP-2834239-A1 | HETEROBICYCLIC COMPOUNDS AS BETA-LACTAMASE INHIBITORS | Astrazeneca AB (SE) | 2015-02-11 | — | — | EP | disclosed |
| US-8598400-B2 | Efficient methods for Z- or cis-selective cross-metathesis | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-12-03 | — | — | US | disclosed |
| WO-2013150296-A1 | HETEROBICYCLIC COMPOUNDS AS BETA-LACTAMASE INHIBITORS | ASTRAZENECA AB (SE) | 2013-10-10 | — | — | WO | disclosed |
| US-8552242-B2 | — | — | 2013-10-08 | — | — | US | disclosed |
| US-20110245477-A1 | EFFICIENT METHODS FOR Z- OR CIS-SELECTIVE CROSS-METATHESIS | TRUSTEES OF BOSTON COLLEGE (US) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245477-A1 | EFFICIENT METHODS FOR Z- OR CIS-SELECTIVE CROSS-METATHESIS | PAICS, COASY, CYP51A1 | ALDH1A1 701/4885CASP3 1161/4885TDP1 3031/4885 |
| US-20190202832-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | LCT, MGAM, MRPL21 | ALDH1A1 214/4885CASP3 3962/4885TDP1 3302/4885 |
| US-20160175290-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | LCT, MGAM, SI | ALDH1A1 319/4885CASP3 3782/4885TDP1 2750/4885 |
| US-10800778-B2 | Beta-lactamase inhibitor compounds | LCT, MGAM, MRPL21 | ALDH1A1 214/4885CASP3 3962/4885TDP1 3302/4885 |
| US-20150073011-A1 | Beta-Lactamase Inhibitor Compounds | LCT, MGAM, SI | ALDH1A1 319/4885CASP3 3782/4885TDP1 2750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.